company background image

Bliss GVS Pharma BSE:506197 Stock Report

Last Price


Market Cap







19 May, 2022


Company Financials
506197 fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health6/6

506197 Stock Overview

Bliss GVS Pharma Limited develops, manufactures, and markets pharmaceutical formulations in India.

Bliss GVS Pharma Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Bliss GVS Pharma
Historical stock prices
Current Share Price₹71.45
52 Week High₹128.40
52 Week Low₹66.25
1 Month Change-11.79%
3 Month Change-16.92%
1 Year Change-34.18%
3 Year Change-56.59%
5 Year Change-62.25%
Change since IPO27,978.63%

Recent News & Updates

Shareholder Returns

506197IN PharmaceuticalsIN Market

Return vs Industry: 506197 underperformed the Indian Pharmaceuticals industry which returned -10.9% over the past year.

Return vs Market: 506197 underperformed the Indian Market which returned 10.5% over the past year.

Price Volatility

Is 506197's price volatile compared to industry and market?
506197 volatility
506197 Average Weekly Movement7.0%
Pharmaceuticals Industry Average Movement7.0%
Market Average Movement7.3%
10% most volatile stocks in IN Market10.0%
10% least volatile stocks in IN Market4.8%

Stable Share Price: 506197 is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: 506197's weekly volatility (7%) has been stable over the past year.

About the Company

1984683Gagan Sharma

Bliss GVS Pharma Limited develops, manufactures, and markets pharmaceutical formulations in India. The company offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear drops, injections, liquid preparations, lotions, lozenges, nasal solutions, oral solids, parenterals, pessaries, sachets, soft gelatin capsules, suppositories, suspensions, syrups, tablets, topical preparations, and transdermal patches. It also provides other healthcare products, such as balms, creams, lotions, lozenges, nasal inhalers, over the counter products, petroleum jellies, powders, roll-ons, shampoos, soaps, solutions, sprays, syrups, and vaginal washes.

Bliss GVS Pharma Fundamentals Summary

How do Bliss GVS Pharma's earnings and revenue compare to its market cap?
506197 fundamental statistics
Market Cap₹7.41b
Earnings (TTM)₹150.40m
Revenue (TTM)₹7.47b


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
506197 income statement (TTM)
Cost of Revenue₹3.91b
Gross Profit₹3.56b
Other Expenses₹3.41b

Last Reported Earnings

Mar 31, 2022

Next Earnings Date


Earnings per share (EPS)1.45
Gross Margin47.69%
Net Profit Margin2.01%
Debt/Equity Ratio12.4%

How did 506197 perform over the long term?

See historical performance and comparison



Current Dividend Yield


Payout Ratio

Does 506197 pay a reliable dividends?

See 506197 dividend history and benchmarks
When do you need to buy 506197 by to receive an upcoming dividend?
Bliss GVS Pharma dividend dates
Ex Dividend DateJun 20 2022
Dividend Pay DateJul 28 2022
Days until Ex dividend31 days
Days until Dividend pay date69 days

Does 506197 pay a reliable dividends?

See 506197 dividend history and benchmarks


Is Bliss GVS Pharma undervalued compared to its fair value and its price relative to the market?

Valuation Score


Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: 506197 (₹71.45) is trading below our estimate of fair value (₹847.86)

Significantly Below Fair Value: 506197 is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: 506197 is poor value based on its PE Ratio (49.3x) compared to the Indian Pharmaceuticals industry average (21.7x).

PE vs Market: 506197 is poor value based on its PE Ratio (49.3x) compared to the Indian market (20.7x).

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 506197's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: 506197 is good value based on its PB Ratio (0.9x) compared to the IN Pharmaceuticals industry average (2.6x).

Future Growth

How is Bliss GVS Pharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Bliss GVS Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Bliss GVS Pharma performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 506197 has a large one-off loss of ₹735.9M impacting its March 31 2022 financial results.

Growing Profit Margin: 506197's current net profit margins (2%) are lower than last year (11.9%).

Past Earnings Growth Analysis

Earnings Trend: 506197's earnings have declined by 8.2% per year over the past 5 years.

Accelerating Growth: 506197's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 506197 had negative earnings growth (-78%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (12.5%).

Return on Equity

High ROE: 506197's Return on Equity (2.7%) is considered low.

Financial Health

How is Bliss GVS Pharma's financial position?

Financial Health Score


Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 506197's short term assets (₹7.8B) exceed its short term liabilities (₹2.3B).

Long Term Liabilities: 506197's short term assets (₹7.8B) exceed its long term liabilities (₹292.0M).

Debt to Equity History and Analysis

Debt Level: 506197 has more cash than its total debt.

Reducing Debt: 506197's debt to equity ratio has reduced from 40.7% to 12.4% over the past 5 years.

Debt Coverage: 506197's debt is well covered by operating cash flow (129.1%).

Interest Coverage: 506197's interest payments on its debt are well covered by EBIT (21.3x coverage).

Balance Sheet


What is Bliss GVS Pharma current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 2/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


Current Dividend Yield

Upcoming Dividend Payment

TodayMay 20 2022Ex Dividend DateJun 20 2022Dividend Pay DateJul 28 202238 days from Ex DividendBuy in the next 31 days to receive the upcoming dividend

Dividend Yield vs Market

Notable Dividend: 506197's dividend (0.7%) is higher than the bottom 25% of dividend payers in the Indian market (0.35%).

High Dividend: 506197's dividend (0.7%) is low compared to the top 25% of dividend payers in the Indian market (1.57%).

Stability and Growth of Payments

Stable Dividend: 506197's dividend payments have been volatile in the past 10 years.

Growing Dividend: 506197's dividend payments have fallen over the past 10 years.

Earnings Payout to Shareholders

Earnings Coverage: With its reasonably low payout ratio (34.2%), 506197's dividend payments are well covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: With its low cash payout ratio (8.4%), 506197's dividend payments are thoroughly covered by cash flows.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Gagan Sharma (38 yo)





Mr. Gagan Harsh Sharma serves as Managing Director & Director at Bliss GVS Pharma Limited since May 11, 2021. He served as Vice President of Strategy and Business Development at Bliss Gvs Pharma Limited un...

CEO Compensation Analysis

Compensation vs Market: Gagan's total compensation ($USD16.85K) is below average for companies of similar size in the Indian market ($USD38.73K).

Compensation vs Earnings: Insufficient data to compare Gagan's compensation with company performance.

Leadership Team

Experienced Management: 506197's management team is considered experienced (3.8 years average tenure).

Board Members

Experienced Board: 506197's board of directors are considered experienced (8.4 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: 506197 insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

Bliss GVS Pharma Limited's employee growth, exchange listings and data sources

Key Information

  • Name: Bliss GVS Pharma Limited
  • Ticker: 506197
  • Exchange: BSE
  • Founded: 1984
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: ₹7.408b
  • Shares outstanding: 103.68m
  • Website:

Number of Employees


  • Bliss GVS Pharma Limited
  • 102, Hyde Park
  • Saki Vihar Road
  • Mumbai
  • Maharashtra
  • 400072
  • India


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/19 00:00
End of Day Share Price2022/05/19 00:00
Annual Earnings2022/03/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.